Critical Survey: Cellular Dynamics International (ICEL) and Its Competitors

Cellular Dynamics International (NASDAQ: ICEL) is one of 182 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Cellular Dynamics International to similar companies based on the strength of its valuation, analyst recommendations, profitability, risk, institutional ownership, dividends and earnings.

Profitability

This table compares Cellular Dynamics International and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellular Dynamics International -88.12% -57.59% -38.09%
Cellular Dynamics International Competitors -4,595.00% -485.74% -42.62%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cellular Dynamics International and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellular Dynamics International 0 0 0 0 N/A
Cellular Dynamics International Competitors 550 2491 6727 132 2.65

As a group, “Biotechnology & Medical Research” companies have a potential upside of 10.41%. Given Cellular Dynamics International’s rivals higher probable upside, analysts clearly believe Cellular Dynamics International has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares Cellular Dynamics International and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cellular Dynamics International N/A N/A -8.53
Cellular Dynamics International Competitors $217.40 million -$39.57 million -45.35

Cellular Dynamics International’s rivals have higher revenue, but lower earnings than Cellular Dynamics International. Cellular Dynamics International is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

48.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cellular Dynamics International Company Profile

Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.

Receive News & Ratings for Cellular Dynamics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Dynamics International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply